NR4A1 and breast carcinoma: Therefore, early breast cancer patients with either high-risk hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) positive, triple-negative, inflammatory or locally advanced breast cancer are eligible for neoadjuvant chemotherapy [4].